Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced NSCLC With EGFR Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05767866
What this trial is testing

Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR

Who this might be right for
TreatmentTreatment Side Effects
Suzhou Puhe Pharmaceutical Technology Co., LTD 160
Very early researchNot Yet RecruitingNCT07458919
What this trial is testing

Therapy for Advanced NSCLC With EGFR 19delins Mutation

Who this might be right for
Lung Cancer
Fuzhou General Hospital 94
Testing effectiveness (Phase 2)Study completedNCT02414139
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 373
Large-scale testing (Phase 3)UnknownNCT02886195
What this trial is testing

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC

Who this might be right for
EGFR Gene Mutation
Fujian Cancer Hospital 120
Not applicableStudy completedNCT02777567
What this trial is testing

KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 315
Testing effectiveness (Phase 2)Looking for participantsNCT05967689
What this trial is testing

Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Who this might be right for
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc. 220
Not applicableUnknownNCT04970043
What this trial is testing

Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment

Who this might be right for
Lung Cancer Stage II
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 58
Testing effectiveness (Phase 2)Active Not RecruitingNCT04504071
What this trial is testing

Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

Who this might be right for
Non-small Cell Lung Cancer MetastaticEGF-R Positive Non-Small Cell Lung Cancer
Shanghai Chest Hospital 30
Large-scale testing (Phase 3)UnknownNCT03074864
What this trial is testing

Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC

Who this might be right for
Non-small Cell Lung CancerEpidermal Growth Factor Receptor
Guangdong Provincial People's Hospital 90
Large-scale testing (Phase 3)UnknownNCT02824458
What this trial is testing

Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

Who this might be right for
EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors
Sun Yat-sen University 246
Testing effectiveness (Phase 2)Study completedNCT01620190
What this trial is testing

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer

Who this might be right for
Recurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer
University of Washington 26
Testing effectiveness (Phase 2)Looking for participantsNCT05948813
What this trial is testing

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Who this might be right for
NSCLCEGFR Activating MutationBrain Metastases
TYK Medicines, Inc 420
Large-scale testing (Phase 3)UnknownNCT00637910
What this trial is testing

Tarceva Italian Lung Optimization tRial

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)
Fatebenefratelli and Ophthalmic Hospital 850
Testing effectiveness (Phase 2)UnknownNCT02930954
What this trial is testing

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

Who this might be right for
Non-small-cell Lung Cancer
Caicun Zhou 180
Not applicableStudy completedNCT04795245
What this trial is testing

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

Who this might be right for
Non-squamous, Non-Small Cell Lung Cancer
Boehringer Ingelheim 805
Testing effectiveness (Phase 2)UnknownNCT05552781
What this trial is testing

H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC

Who this might be right for
Non-small Cell Lung Cancer
RedCloud Bio 76
Early research (Phase 1)Study completedNCT02157883
What this trial is testing

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

Who this might be right for
Advanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung Cancer
AstraZeneca 39
Testing effectiveness (Phase 2)Study completedNCT03386955
What this trial is testing

BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Beta Pharma Shanghai 215
Not applicableStudy completedNCT03790397
What this trial is testing

Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive

Who this might be right for
Non Small Cell Lung Cancer
Fundación GECP 169
Not applicableStudy completedNCT04206787
What this trial is testing

The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-squamous, Non-Small Cell Lung Cancer
Boehringer Ingelheim 72
Next Page